July 28, 2017
Paris office advises Ekkio Capital on the signing of an exclusive agreement for the sale of the Amatsigroup to Eurofins, the world leader in bio-pharmaceutical testing and a world leader in analytical services.
Willkie’s Paris office recently advised Ekkio Capital on the signing of an exclusive agreement for the sale of the Amatsigroup to Eurofins, the world leader in bio-pharmaceutical testing and a world leader in analytical services.
Founded in 2010 by Ekkio Capital, Amatsigroup was formed through the merger of four companies (Avogadro, Amatsi, DBI and Avepharm), and has grown though several strategic acquisitions. Eurofins is a leading international contract development and manufacturing organization (CDMO) providing preclinical and clinical services for the development of human and veterinary drugs. Ekkio Capital is an independent private equity firm funded by institutional investors investing in high potential growth French and European SMEs.
The Willkie deal team was led by partner Christophe Garaud with the assistance of associate Virginie Sayag. Counsel Philippe Grudé advised on tax aspects on the transaction.
